The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
An HTLV-I Vaccine: Why, How, for Whom?
Abstract
Endemic infection with the human T cell leukemia/lymphoma viruses I and II (HTLV-I/II) is now recognized to be worldwide, and is becoming epidemic among intravenous drug abusers (IVDAs) in the United States and Europe. The number of people around the world infected with HTLV-I can be estimated as between 10 and 20 million (Table 1). HTLV-I causes a rapidly progressing adult T cell leukemia/lymphoma (ATLL), and an incurable progressive neuromyelopathy named tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM), as well as a number of less well-studied syndromes. There is evidence that coinfection with HTLV-I or -II accelerates progression to AIDS. The cumulative lifetime risk of developing ATLL or TSP/HAM is around 5%, which, in terms of the induction of serious diseases, places HTLV-I in the same category of viruses for which efficient vaccines are made and used. Furthermore, there are factors favoring the feasibility of a vaccine against HTLV-I, in that the virus displays relatively low antigenic variability, natural immunity occurs in humans, and experimental vaccination with the envelope (Env) antigen is successful in animal models. A vaccine against HTLV-I would be of significant public health value in the fields of oncology, neurology, and AIDS, and it would serve as a pathfinder for a vaccine against HIV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043
ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESIS
Gessain, A., Vernant, J. C., Maurs, L., Barin, F., Gout, O., Calender, A., & De Thé, G. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92734-5 · Cited by 2,843
Self-citationNew use of BCG for recombinant vaccines
Stover, C. K., de la Cruz, V. F., Fuerst, T. R., Burlein, J. E., Benson, L. A., Bennett, L. T., Bansal, G. P., Young, J. F., Lee, M. H., Hatfull, G. F., et al. (1991) · Nature · doi:10.1038/351456a0 · Cited by 1,490
Kalyanaraman, V. S., Sarngadharan, M. G., Robert-Guroff, M., Miyoshi, I., Blayney, D., Golde, D., & Gallo, R. C. (1982) · Science · doi:10.1126/science.6981847 · Cited by 1,196
Okochi, K., Sato, H., & Hinuma, Y. (1984) · Vox Sanguinis · doi:10.1111/j.1423-0410.1984.tb00083.x · Cited by 663
Jacobson, S., Shida, H., McFarlin, D. E., Fauci, A. S., & Koenig, S. (1990) · Nature · doi:10.1038/348245a0 · Cited by 613
Infective dermatitis of Jamaican children: a marker for HTLV-I infection
Blattner, W., LaGrenade, L., Hanchard, B., Fletcher, V., & Cranston, B. (1990) · The Lancet · doi:10.1016/0140-6736(90)92896-p · Cited by 453
High Rate of HTLV-II Infection in Seropositive IV Drug Abusers in New Orleans
Lee, H., Swanson, P., Shorty, V. S., Zack, J. A., Rosenblatt, J. D., & Chen, I. S. Y. (1989) · Science · doi:10.1126/science.2655084 · Cited by 424
Murphy, E. L., Hanchard, B., Figueroa, J. P., Gibbs, W. N., Lofters, W. S., Campbell, M., Goedert, J. J., & Blattner, W. A. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430214 · Cited by 404
Kaplan, J. E., Osame, M., Kubota, H., Igata, A., Nishitani, H., Maeda, Y., KHABBAZ, R. F., & Janssen, R. S. (1990) · PubMed · Cited by 369
Cited by
Epidemiological Aspects and World Distribution of HTLV-1 Infection
Gessain, A., & Cassar, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00388 · Cited by 1,428
Human T-lymphotropic virus 1: recent knowledge about an ancient infection
Verdonck, K., González, E., Van Dooren, S., Vandamme, A.-M., Vanham, G., & Gotuzzo, E. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70081-6 · Cited by 661
Human T-lymphotropic virus type I infection
Manns, A., Hisada, M., & Grenade, L. L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09460-4 · Cited by 360
Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma
Ishitsuka, K., & Tamura, K. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70202-5 · Cited by 343
Yamano, Y., Nagai, M., Brennan, M., Mora, C. A., Soldan, S. S., Tomaru, U., Takenouchi, N., Izumo, S., Osame, M., & Jacobson, S. (2002) · Blood · doi:10.1182/blood.v99.1.88 · Cited by 279
Metadata
- Authors
- DE THÉ, G., & BOMFORD, R.
- Venue
- AIDS Research and Human Retroviruses
- Publisher
- SAGE Publications
- Published
- 1993-05
- Volume
- 9
- Issue
- 5
- Pages
- 381-386
- ISSN
- 0889-2229 (ISSN-L)
- 1931-8405
- OpenAlex
- W2030973107
- Cited by
- 272
- References
- 47
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An HTLV-I Vaccine: Why, How, for Whom? https://app.cochat.ai/papers/10.1089/aid.1993.9.381
- The paper
- DE THÉ, G., & BOMFORD, R. (1993). An HTLV-I Vaccine: Why, How, for Whom? AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.1993.9.381
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.